Medical
-
Blue Lake Biotechnology announced that it has received a $5 million grant from the Gates Foundation to support the addition of younger children to a Phase 1/2a clinical trial of its BLB201 nasal vaccine against… Read more . . .
-
Israeli biotech Nano24 announced that a Phase 2b trial of nebulized EXO-CD24 exosomes in patients with acute respiratory distress syndrome met its primary endpoint, with 85% of patients who received EXO-CD24 having an SpO2/FiO2 >315… Read more . . .
-
According to United Therapeutics, the FDA has cleared the company’s IND for the 16-week Phase 2 SUMMIT trial of treprostinil SMI in patients with pulmonary hypertension associated with COPD, which is expected to enroll approximately… Read more . . .
-
Nasus Pharma has announced the initiation of a Phase 1 PK study of its NS003 nasal powder ondansetron, which the company is developing for the treatment of nausea and vomiting following surgical procedures or chemotherapy.… Read more . . .
-
California-based startup Mosanna Therapeutics, which raised $80 million last year for clinical development of MOS118 nasal spray for the treatment of obstructive sleep apnea, said that results from a Phase 1 study support progression into… Read more . . .
-
Tiziana Life Sciences has announced the initiation of the Phase 2a Healey ALS MyMatch BANYAN trial of intranasal foralumab in people with amyotrophic lateral sclerosis. The company announced in November 2024 the ALS Association would… Read more . . .
-
Kither Biotech has announced the initiation of a Phase 1b /2a study of KIT2014 inhaled PDE3/4 inhibitor in patients with COPD. The company recently announced results from a Phase 1 trial of KIT2014 in healthy… Read more . . .
-
Chinese OINDP developer CF Pharmtech has announced the initiation of its Phase 1 trial of its ICF004 dry powder inhaler, which the company is developing for the treatment of fibrotic lung diseases. The study record… Read more . . .
-
Polyrizon has announced the initiation of its first clinical trial, a study of its Nasarix (PL-14) hydrogel nasal spray in patients with seasonal allergic rhinitis. In September 2025, the company said that it had submitted… Read more . . .
-
SpliSense announced that it has initiated the Phase 2b portion of the SPL84-02 trial of the SPL84 inhaled antisense oligonucleotide in CF patients with the 3849+10kb C→T splicing mutation in the CFTR gene. The Phase… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 30: RespireX 2027, Boston, MA, USA